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Background: Cholera is the most severe of acute diarrhea epi-
demiccausedbyV. cholerae. It is classiﬁed into twobiotypes: classic
and El Tor, and three serotypes: Inaba, Ogawa and Hikojima. The
ﬁrst six cholera pandemics were caused by the classical biotype. In
1961, El Tor replaced the classical biotype upon occurrence of the
seventh pandemic. Since the last decade, a new variant of El Tor has
been documented. The project objective was to investigate the V.
cholerae strains circulating in sanctuaries sites in DRC.
Methods & Materials: Phenotypic and genotypic characteriza-
tion of ten strains of V. cholerae O1fromKalemie and Uvira isolated
in 2014 and 2015 were investigated by classical bacteriological
techniques, PCR and PFGE.
Results: These strains belong to the El Tor biotype and serotype
Ogawa. The presence of ctxB1 virulence gene suggests the exis-
tence of a variant of El Tor. Strains from Kalémie presented
four antibiotic resistance (colistin, nitrofurans, nalidixic acid and
Norﬂoxacin) whereas Uvira resistance was observed for seven
antibiotics (colistin, nitrofurans, nalidixic acid, Norﬂoxacin, Sulfon-
amides, Streptomycin Sulfonamides and trimethoprim Quinolone
resistance and mutations on gyrA and parC genes were observed.
The molecular genotyping method in this study; the pulsed ﬁeld
coupled to two enzymes Not I and Sﬁ I allowed to differentiate two
different strains circulating in Uvira and Kalemie.
Conclusion: Two different strains circulating in Uvira and
Kalemie have been highlighted both by their PFGE proﬁles and
antibiotic resistance.
http://dx.doi.org/10.1016/j.ijid.2016.02.338
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Background: Background: Infective endocarditis (IE) is a
microbial infection of the endothelial surface of the cardiac valves.
Despite advances it is associated with morbidity and mortality.
Rapid diagnosis, effective treatment, and prompt recognition of
complications are essential for good patient outcome.
Methods & Materials: Materials and methods: The medical
records of 191 patients clinically diagnosed with infective endo-
carditis were reviewed for clinical and microbiology data admitted
between January 2011 to Sep 2015. Blood cultures were detected
by using BacT/Alert FAN and SN aerobic bottles.68/191 cases were
positive for bacterial pathogens. The isolates were identiﬁed and
sensitivity was tested using API and Vitek 2 systems
Results: Results: The age range of the patients were17-54
years with a female preponderance. Chronic Rheumatic heart dis-
ease (CRHD) was the most common predisposing factor followed
by valvular abnormalities, mostly mitral stenosis. 24/191 cases
had Prosthetic valve endocarditis (PVE), 167/191 had Native valve
endocarditis (NVE).19/24(79.1%) PVE cases and 49/167 (29.34%)
NVE were culture positive. Culture negative endocarditis was
123/191(64.39%).
Isolates for NVE belonged to the Streptococcus species
and include Streptococcus mitis (15) Streptococcus sanguinis (8)
Streptococcus pyogenes (3), Streptococcus pneumonia (1), Entero-
coccus faecalis (5), Enterococcus faecium (6), Nutritionally variant
streptococci (2),Gemella morbillorum (2) Methicillin Resistant
Staphylococcus aureus (1) Methicillin Sensitive Staphylococcus
aureus (2),Brucella melitensis (2),and also includes Brevundimonas
diminuta (1),Corynebacterium diphtheria (1).
The isolates for PVE were Methicillin Resistant Staphylococcus
aureus (4),Methicillin Sensitive Staphylococcus aureus (2) Methi-
cillin Resistant coagulase negative Staphylococcus (7), Klebsiella
pneumonia (3),Achromobacter denitriﬁcans (1), Burkholderia.cepacia
(2)
The NVE were treated with a combination of a B-lactam or
glycopeptide with an aminoglycoside intravenously for prolonged
period of 4-6 weeks with a successful outcome The PVE cases were
treated with the appropriate antibiotics as per the antibiotic sus-
ceptibility report.
Conclusion:Conclusion: Despite recent advances, themanage-
ment of IE remains a serious and challenging problem The high
morbidity and mortality rates, accurate identiﬁcation of aetiolog-
ical agents and appropriate antimicrobial therapy are associated
with IE. Strict infection control measures will help to reduce the
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incidence of PVE, which is most often due to hospital acquired
pathogens
http://dx.doi.org/10.1016/j.ijid.2016.02.339
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Background: Staphylococcus aureus bacteremia (SAB) is one
of the serious nosocomial or community acquired infections. SAB
can persist longer as compared to bacteremia with other bacteria,
althoughwhether risk factors associatedwith persistent SABwhich
pointed out in previous studies are related to its persistency of SAB
in the settings with different antibiotic resistant rate and different
antibiotic use. In this study, we determined clinical characteristics
and risk factors for persistent SAB by comparing persistent SAB
cases and non-persistent SAB cases in Japan.
Methods & Materials: All the ﬁrst episodes of adult SAB cases
in 1,150 bed academic medical hospital in Japan form May 2009
through April 2014 were enrolled. The onset of SAB was deﬁned
as the time when the ﬁrst positive blood cultures were collected.
Persistent SABwas deﬁned as a case inwhich positive blood culture
persisted 72 hours or longer, and non-persistent SAB was deﬁned
as a case negativity of blood culture was veriﬁed within 72 hours.
Clinical backgrounds, primary infection sites, methicillin resistant
or not (MRSA or MSSA), vancomycin susceptibility, and antibiotic
use were retrospectively reviewed from medical records.
Results: Of 618 SAB cases, MRSA cases and MSSA cases were
293 and 325 cases, respectively. Persistent SAB were 42 cases,
non-persistent SAB were 34 cases. Median persistent periods of
persistent SAB and non-persistent SAB were 2 days and 8 days,
respectively. Clinical backgrounds and primary infection sites pri-
mary infection sites were similar between the two groups. The rate
of MRSA was in persistent SAB was statistically higher than that
of non-persistent SAB (93% vs 35%, P<0.001)(Fig. 1). Although sus-
ceptibilities to vancomycin, were similar between the two groups,
the timing of susceptible antibiotics use in persistent SAB was later
than that in non-persistent SAB (2 days vs 0 days, P <0.001) (Fig. 2).
Fig. 1. Methicillin susceptibility of SA and SAB persistence.
Fig. 2. Delay of antibiotic use and SAB persistence.
Conclusion: In our study, persistence of SAB were associated
with MRSA as a pathogen, delay in susceptible antibiotic use, but
notwith clinical backgroundsnorwithvancomycin susceptibilities.
http://dx.doi.org/10.1016/j.ijid.2016.02.340
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Background: The rising incidence and worsening severity of
Clostridium difﬁcile infection (CDI) have prompted improvements
in the treatment of CDI in many countries. Vancomycin (VCM) and
Metronidazole (MNZ) are both widely used. VCM may bring about
a better clinical response and outcome than MNZ in treating CDI,
especially severe CDI. The optimal treatment for CDI, however, has
yet tobeestablished in Japan.Dosages anddurationsofmedications
for CDI have not been clearly described in previous studies, and
MNZ has only recently been approved for CDI under the national
health insurance system. Our group conducted Japan’s ﬁrst multi-
center retrospective study to investigate the optimal treatment
for CDI by comparing outcomes between MNZ- and VCM-treated
groups at variable dosages and treatment durations.
Methods & Materials: CDI patients hospitalized at four teach-
ing hospitals from April 2012 through September 2013 were
enrolled. CDIwasdiagnosedwhenCD toxinwaspositivebyenzyme
immunoassay test in stool. Thepatientswere treated for 10-14days
with oral MNZ (1000 or 1500 mg per day: MNZ group) or oral VCM
(500 mg per day: VCM group). Kaplan-Meier curves were created
to compare the survival curves between MNZ- and VCM-treated
patients.
